Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen Inc.
Gene therapy reverses established osteopenia in ovariectomized mice
June 26th, 2004
Pathologists at Amgen Inc. were able to reverse osteopenia in ovariectomized mice by using an adeno-associated virus to deliver an osteoclast-inhibiting protein. "Osteoporosis is a chronic condition that is typically treated by the long-term repeated administration of antiresorptive agents. Gene therapy has the potential to deliver protein-based antiresorptive agents without the need for repeated administration. Osteoprotegerin (OPG) is a naturally occurring protein that prevents bone resorption by inhibiting osteoclast formation, function, and survival," wrote P.J. Kostenuik and colleagues. They conducted experiments in ovariectomized (OVX) mice to...
Source: Law & Health Weekly (2004-06-26)
|
